<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03803631</url>
  </required_header>
  <id_info>
    <org_study_id>COCTAEyl</org_study_id>
    <nct_id>NCT03803631</nct_id>
  </id_info>
  <brief_title>CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)</brief_title>
  <acronym>COCTAEyl</acronym>
  <official_title>CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to analyze a new noninvasive imaging examination, OCT&#xD;
      angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet&#xD;
      AMD undergoing treatment on OCTA and to correlate OCTA findings with SD-OCT findings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at baseline</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 1</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 2</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 3</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 4</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 5</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 6</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 7</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 8</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 9</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 10</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 11</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 12</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 13</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of hemorrhage, fibrosis and atrophy on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of hemorrhage on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of fibrosis on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of atrophy on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of hemorrhage on fundus color photography</measure>
    <time_frame>at 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of fibrosis on fundus color photography</measure>
    <time_frame>at 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of atrophy on fundus color photography</measure>
    <time_frame>at 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on fluorescein angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on fluorescein angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>at month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on indocyanine green angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on indocyanine green angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>at month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>choroidal thickness on EDI-OCT</measure>
    <time_frame>monthly during 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on SD-OCT (type 1, type 2 or mixed lesions)</measure>
    <time_frame>monthly during 13 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">49</enrollment>
  <condition>AMD</condition>
  <condition>Exudative Macular Degeneration</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with wet-AMD (NVC type 1 or 2) diagnosed maximum one week before inclusion and for&#xD;
        whom Aflibercept in intra-vitreal injection technic has been prescribed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Naïve patients&#xD;
&#xD;
          -  Type 1 or type 2 Choroidal NeoVascularization (CNV)&#xD;
&#xD;
          -  Age ≥ 55 years&#xD;
&#xD;
          -  Presence of subfoveal CNV secondary to Age-related Macular Degeneration (AMD)&#xD;
&#xD;
          -  At the time of inclusion, multimodal imaging should reveal exudative features&#xD;
&#xD;
          -  Exudative AMD diagnosis established between 1 and 7 days before inclusion&#xD;
&#xD;
          -  Monitored monthly&#xD;
&#xD;
          -  Loading phase then bimonthly retreatment.&#xD;
&#xD;
          -  Signed Informed Consent.&#xD;
&#xD;
          -  Patient covered by the French Health Insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polypoidal choroidal vasculopathy&#xD;
&#xD;
          -  Type 3 neovascularization&#xD;
&#xD;
          -  Choroidal neovascularization attributable to causes other than AMD&#xD;
&#xD;
          -  Macular hematoma&#xD;
&#xD;
          -  Pigment epithelial detachment higher than 150µm&#xD;
&#xD;
          -  Fibrosis &gt; 50% lesion on fundus color photography, fibroglial scar&#xD;
&#xD;
          -  Media opacity annoying acquisition&#xD;
&#xD;
          -  Retinal vascular occlusion&#xD;
&#xD;
          -  Diabetic retinopathy&#xD;
&#xD;
          -  Adult-onset foveomacular vitelliform dystrophy and other pattern dystrophies,&#xD;
&#xD;
          -  Refractive error &gt;-6D&#xD;
&#xD;
          -  Active intraocular inflammation in the study eye&#xD;
&#xD;
          -  Patient who does not meet the local indication criteria for Eylea® treatment.&#xD;
             Contraindications listed in the SmPCs must be taken into account&#xD;
&#xD;
          -  Patient taking part in an interventional study at the time of enrolment.&#xD;
&#xD;
          -  Any history of allergy to the antiseptic used during preparation of the eye for the&#xD;
             IVT injection in the investigational site (e.g. povidone iodine or chlorhexidine).&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Stroke and/or myocardial infarction 3 months before inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Pellegrin, CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Ophtalmologique d'Imagerie et de Laser,</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

